Gouri Koduri
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Gouri Koduri has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Shirish Dubey
Department of Rheumatology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK
4 shared publications - Anupama Nandagudi
Basildon University Hospital, Nether Mayne, Basildon, UK
2 shared publications - Chetan Mukhtyar
Vasculitis Service, Rheumatology Department, Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, UK
2 shared publications Damodar Makkuni
James Paget University Hospital, Lowestoft Rd, Great Yarmouth, UK
2 shared publications- Abhinav Peddasomayajulu
Southend University Hospital, Southend on Sea, UK
1 shared publication Ameen Jubber
Department of Rheumatology, Leicester University Hospital NHS Trust UK
1 shared publication
Latest Publications
- 5 September 2026
- Published by European Respiratory Society (ERS)
- Vol. 68 (suppl 70) , PA4671
Rheumatoid Arthritis–Associated Interstitial Lung Disease: Current Understanding and Insights from a UK Clinician Survey
Background: Rheumatoid arthritis–associated interstitial lung disease (RA‑ILD) is often an underdiagnosed complication of RA. Although ILD is detectable on imaging in 30%–76% of patients, only 10%–15% develop significant disease. RA‑ILD is a major contributor to RA‑related mortality, yet evidence‑based guidance for screening and monitoring remains limited. To understand current UK practice, a national survey was distributed to clinicians involved in RA‑ILD care. Methodology: The survey assessed ILD service availability,MDT access, referral pathways, screening approaches, annual review structures, and diagnostic waiting times. Results: Sixty of 200 clinicians responded. Nineteen reported no dedicated ILD service;27 had a joint Respiratory–Rheumatology service, and 14 had a Respiratory‑led service. MDT access varied:13 had no MDT,while 47 accessed local, regional, or tertiary MDTs. Screening practices were inconsistent:seven undertook no routine screening,28 performed baseline screening, and 21 carried out annual assessments. Twenty‑three screened before starting methotrexate or biologics. Half (n=30) reported no dedicated RA annual review clinic due to capacity constraints. Diagnostic access also varied. HRCT availability was generally timely, with 73% receiving scans within 4–6 weeks. Pulmonary function testing(PFT)showed marked delays:35% reported access within four weeks,25% waited 12–24 weeks, and 18% waited more than 24 weeks. Conclusion: This survey shows wide variation in RA‑ILD service provision,MDT access, screening, and diagnostic pathways across the NHS. HRCT access is generally efficient, but delays in PFT and limited structured review capacity lead to inconsistent monitoring. The findings highlight the need for national guidance, improved service integration and more consistent RA‑ILD management.
- 5 September 2026
- Published by European Respiratory Society (ERS)
- Vol. 68 (suppl 70) , PA4671
Rheumatoid Arthritis–Associated Interstitial Lung Disease: Current Understanding and Insights from a UK Clinician Survey
Background: Rheumatoid arthritis–associated interstitial lung disease (RA‑ILD) is often an underdiagnosed complication of RA. Although ILD is detectable on imaging in 30%–76% of patients, only 10%–15% develop significant disease. RA‑ILD is a major contributor to RA‑related mortality, yet evidence‑based guidance for screening and monitoring remains limited. To understand current UK practice, a national survey was distributed to clinicians involved in RA‑ILD care. Methodology: The survey assessed ILD service availability,MDT access, referral pathways, screening approaches, annual review structures, and diagnostic waiting times. Results: Sixty of 200 clinicians responded. Nineteen reported no dedicated ILD service;27 had a joint Respiratory–Rheumatology service, and 14 had a Respiratory‑led service. MDT access varied:13 had no MDT,while 47 accessed local, regional, or tertiary MDTs. Screening practices were inconsistent:seven undertook no routine screening,28 performed baseline screening, and 21 carried out annual assessments. Twenty‑three screened before starting methotrexate or biologics. Half (n=30) reported no dedicated RA annual review clinic due to capacity constraints. Diagnostic access also varied. HRCT availability was generally timely, with 73% receiving scans within 4–6 weeks. Pulmonary function testing(PFT)showed marked delays:35% reported access within four weeks,25% waited 12–24 weeks, and 18% waited more than 24 weeks. Conclusion: This survey shows wide variation in RA‑ILD service provision,MDT access, screening, and diagnostic pathways across the NHS. HRCT access is generally efficient, but delays in PFT and limited structured review capacity lead to inconsistent monitoring. The findings highlight the need for national guidance, improved service integration and more consistent RA‑ILD management.
- Open Access
- 24 September 2025
- Published by Springer Nature in Rheumatology International
- Vol. 45 (10) , 1-9
Enhanced education and support needs in rheumatoid arthritis associated interstitial lung disease (RA-ILD) – patient experiences from a multicentre UK survey
Objectives: Interstitial lung disease (ILD), one of the complications of rheumatoid arthritis (RA) has significant impact on morbidity and mortality. Very little work has been done on patient perceptions, experiences and their needs in RA-ILD. This study aimed to fill that gap in order to better understand and optimise care pathways. Methods: There are no validated questionnaires, so we piloted and developed one based on Commissioning for Quality in RA Reported Experience Measure (CQRA-PREM). This study was conducted at 6 sites following formal ethics approval. Patients with RA-ILD were identified from routine clinics and databases. Results: We included 64 completed valid responses in the final analysis. Median age of the cohort was 75 years; duration of RA was 7 years. Only 13 (20%) participants received detailed information on ILD. Majority reported negative experiences regarding their involvement in care ( n = 40, 64%) and needed help from family members or carers ( n = 35, 60%). Half were attending respiratory clinics regularly ( n = 34, 53%) or having regular PFTs ( n = 29, 45%). Only 11 (17%) were able to do moderate exercise or higher. Participants desired more information on ILD, frequent appointments with specialists, earlier referral to specialist centre, and improved communication between specialists. Conclusions: This study explores patient perspectives in RA-ILD across 6 different UK socioeconomic areas. There are substantial educational needs, disability, and notable gaps in service provisions. Enhanced patient support is needed, and this necessitates more effective integration and utilisation of the multidisciplinary team, including specialist nurses, psychologists, pharmacists, and other allied health professionals.
- 24 September 2025
- Published by Springer Nature in Rheumatology International
- Vol. 45 (10) , 1-9
Open AccessEnhanced education and support needs in rheumatoid arthritis associated interstitial lung disease (RA-ILD) – patient experiences from a multicentre UK survey
Objectives: Interstitial lung disease (ILD), one of the complications of rheumatoid arthritis (RA) has significant impact on morbidity and mortality. Very little work has been done on patient perceptions, experiences and their needs in RA-ILD. This study aimed to fill that gap in order to better understand and optimise care pathways. Methods: There are no validated questionnaires, so we piloted and developed one based on Commissioning for Quality in RA Reported Experience Measure (CQRA-PREM). This study was conducted at 6 sites following formal ethics approval. Patients with RA-ILD were identified from routine clinics and databases. Results: We included 64 completed valid responses in the final analysis. Median age of the cohort was 75 years; duration of RA was 7 years. Only 13 (20%) participants received detailed information on ILD. Majority reported negative experiences regarding their involvement in care ( n = 40, 64%) and needed help from family members or carers ( n = 35, 60%). Half were attending respiratory clinics regularly ( n = 34, 53%) or having regular PFTs ( n = 29, 45%). Only 11 (17%) were able to do moderate exercise or higher. Participants desired more information on ILD, frequent appointments with specialists, earlier referral to specialist centre, and improved communication between specialists. Conclusions: This study explores patient perspectives in RA-ILD across 6 different UK socioeconomic areas. There are substantial educational needs, disability, and notable gaps in service provisions. Enhanced patient support is needed, and this necessitates more effective integration and utilisation of the multidisciplinary team, including specialist nurses, psychologists, pharmacists, and other allied health professionals.
- Top Cited PapersOpen Access
- 4 October 2023
- Published by Wiley in Arthritis & Rheumatology
- Vol. 75 (12) , 2067-2077
Identification, Monitoring, and Management of Rheumatoid Arthritis–Associated Interstitial Lung Disease
Interstitial lung disease (ILD) is a frequent complication of rheumatoid arthritis (RA) that is associated with a significant increase in mortality. Several risk factors for the development of ILD in patients with RA have been identified, but ILD can still develop in the absence of these risk factors. Screening tools for RA‐ILD are required to facilitate early detection of RA‐ILD. Close monitoring of patients with RA‐ILD for progression is crucial to enable timely implementation of treatment strategies to improve outcomes. Patients with RA are commonly treated with immunomodulatory therapies, although their efficacy in slowing the progression of RA‐ILD remains the subject of debate. Clinical trials have shown that antifibrotic therapies slow decline in lung function in patients with progressive fibrosing ILDs, including patients with RA‐ILD. The management of patients with RA‐ILD should be based on multidisciplinary evaluation of the severity and progression of their ILD and the activity of their articular disease. Close collaboration between rheumatologists and pulmonologists is essential to optimize patient care.
- 4 October 2023
- Published by Wiley in Arthritis & Rheumatology
- Vol. 75 (12) , 2067-2077
Top Cited PapersOpen AccessIdentification, Monitoring, and Management of Rheumatoid Arthritis–Associated Interstitial Lung Disease
Interstitial lung disease (ILD) is a frequent complication of rheumatoid arthritis (RA) that is associated with a significant increase in mortality. Several risk factors for the development of ILD in patients with RA have been identified, but ILD can still develop in the absence of these risk factors. Screening tools for RA‐ILD are required to facilitate early detection of RA‐ILD. Close monitoring of patients with RA‐ILD for progression is crucial to enable timely implementation of treatment strategies to improve outcomes. Patients with RA are commonly treated with immunomodulatory therapies, although their efficacy in slowing the progression of RA‐ILD remains the subject of debate. Clinical trials have shown that antifibrotic therapies slow decline in lung function in patients with progressive fibrosing ILDs, including patients with RA‐ILD. The management of patients with RA‐ILD should be based on multidisciplinary evaluation of the severity and progression of their ILD and the activity of their articular disease. Close collaboration between rheumatologists and pulmonologists is essential to optimize patient care.
- Open Access
- 18 April 2023
- Published by Springer Nature in Rheumatology International
- Vol. 43 (8) , 1515-1523
Four-factor risk score for the prediction of interstitial lung disease in rheumatoid arthritis
Objective: Interstitial lung disease (ILD) is one of the commonest systemic complications in patients with rheumatoid arthritis (RA) and carries a significant morbidity and mortality burden. We aimed to identify key variables to risk-stratify RA patients in order to identify those at increased risk of developing ILD. We propose a probability score based on the identification of these variables. Methods: A retrospective, multicentre study using clinical data collected between 2010 and 2020, across 20 centres. Results: A total of 430 RA (210 with ILD confirmed on high-resolution computed tomography (HRCT)) patients were evaluated. We explored several independent variables for the risk of developing ILD in RA and found that the key significant variables were smoking (past or present), older age and positive rheumatoid factor/anti-cyclic citrullinated peptide. Multivariate logistic regression models were used to form a scoring system for categorising patients into high and low risk on a scale of 0–9 points and a cut-off score of 5, based on the area under the receiver operating characteristic curve of 0.76 (CI 95% 0.71–0.82). This yielded a sensitivity of 86% and a specificity of 58%. High-risk patients should be considered for investigation with HRCT and monitored closely. Conclusion: We have proposed a new model for identifying RA patients at risk of developing ILD. This approach identified four simple clinical variables: age, anti-cyclic citrullinated peptide antibodies, Rheumatoid factor and smoking, which allowed development of a predictive scoring system for the presence of ILD in patients with RA.
- 18 April 2023
- Published by Springer Nature in Rheumatology International
- Vol. 43 (8) , 1515-1523
Open AccessFour-factor risk score for the prediction of interstitial lung disease in rheumatoid arthritis
Objective: Interstitial lung disease (ILD) is one of the commonest systemic complications in patients with rheumatoid arthritis (RA) and carries a significant morbidity and mortality burden. We aimed to identify key variables to risk-stratify RA patients in order to identify those at increased risk of developing ILD. We propose a probability score based on the identification of these variables. Methods: A retrospective, multicentre study using clinical data collected between 2010 and 2020, across 20 centres. Results: A total of 430 RA (210 with ILD confirmed on high-resolution computed tomography (HRCT)) patients were evaluated. We explored several independent variables for the risk of developing ILD in RA and found that the key significant variables were smoking (past or present), older age and positive rheumatoid factor/anti-cyclic citrullinated peptide. Multivariate logistic regression models were used to form a scoring system for categorising patients into high and low risk on a scale of 0–9 points and a cut-off score of 5, based on the area under the receiver operating characteristic curve of 0.76 (CI 95% 0.71–0.82). This yielded a sensitivity of 86% and a specificity of 58%. High-risk patients should be considered for investigation with HRCT and monitored closely. Conclusion: We have proposed a new model for identifying RA patients at risk of developing ILD. This approach identified four simple clinical variables: age, anti-cyclic citrullinated peptide antibodies, Rheumatoid factor and smoking, which allowed development of a predictive scoring system for the presence of ILD in patients with RA.
- Open Access
- 29 March 2022
- Published by Oxford University Press (OUP) in Rheumatology Advances in Practice
- Vol. 6 (1) , rkac022
Is increasing patient participation in rheumatoid arthritis disease management the key to better treatment adherence?
Early intensive treatments for RA, including combination therapy, are being used to achieve remission or a low disease activity state. Furthermore, it is increasingly recognized that decision-making should be balanced and shared between the patient and the clinician.
- 29 March 2022
- Published by Oxford University Press (OUP) in Rheumatology Advances in Practice
- Vol. 6 (1) , rkac022
Open AccessIs increasing patient participation in rheumatoid arthritis disease management the key to better treatment adherence?
Early intensive treatments for RA, including combination therapy, are being used to achieve remission or a low disease activity state. Furthermore, it is increasingly recognized that decision-making should be balanced and shared between the patient and the clinician.
- 1 September 2021
- Published by Elsevier in Autoimmunity Reviews
- Vol. 20 (9) , 102883
Rheumatological complications of Covid 19
- 1 September 2021
- Published by Elsevier in Autoimmunity Reviews
- Vol. 20 (9) , 102883
Rheumatological complications of Covid 19
- 1 May 2021
- Published by SAGE Publications in Indian Journal of Rheumatology
- Vol. 16 (1S) , 20-28
Spectrum of Interstitial Lung Disease in Rheumatic Diseases
Are associated with several mechanisms, particularly the inflammatory processes of immune cells and also fibrotic processes, which play a crucial role in disease progression, making immunosuppressive therapy less effective. However, recent advances in pharmacologic interventions have been shown to delay disease progression of these lung conditions and improve patient survival. Disease stratification and early identification of patients who are more likely to progress, and thus in need of more aggressive treatment, is important in the field of ILD. Early diagnosis, monitoring, and multidisciplinary team input are very important to improve overall outcomes. This review focuses on ILD in patients with various rheumatic diseases (rheumatoid arthritis, myositis, Sjogren' syndrome, and systemic sclerosis) and the challenges....
- 1 May 2021
- Published by SAGE Publications in Indian Journal of Rheumatology
- Vol. 16 (1S) , 20-28
Spectrum of Interstitial Lung Disease in Rheumatic Diseases
Are associated with several mechanisms, particularly the inflammatory processes of immune cells and also fibrotic processes, which play a crucial role in disease progression, making immunosuppressive therapy less effective. However, recent advances in pharmacologic interventions have been shown to delay disease progression of these lung conditions and improve patient survival. Disease stratification and early identification of patients who are more likely to progress, and thus in need of more aggressive treatment, is important in the field of ILD. Early diagnosis, monitoring, and multidisciplinary team input are very important to improve overall outcomes. This review focuses on ILD in patients with various rheumatic diseases (rheumatoid arthritis, myositis, Sjogren' syndrome, and systemic sclerosis) and the challenges....
- Open Access
- 11 January 2021
- Published by Oxford University Press (OUP) in Rheumatology Advances in Practice
- Vol. 5 (1) , rkaa076
Patient perceptions of co-morbidities in inflammatory arthritis
Objective: Longer life expectancy has resulted in people living with an increasing number of co-morbidities. The average individual with inflammatory arthritis has two co-morbidities, which contribute to higher mortality, poorer functional outcomes and increased health-care utilization and cost. A number of studies have investigated the prevalence of co-morbidities, whereas this study was designed to look at patient perspectives. Methods: The study comprised two parts: a patient questionnaire and an interview. Individuals with physician-verified inflammatory arthritis along with one or more Charlson co-morbidities were invited to participate. In-depth data were obtained by interviews with 12 willing participants. Results: One hundred and forty-six individuals were recruited; 50 (35%) had one co-morbidity, 69 (48%) had two and 25 (17%) had more than four co-morbidities. Seventy-seven individuals (53%) reported that co-morbidities affected their health as much as their arthritis, and 82 (56%) reported dependence on others for activities of daily living. Lack of education was highlighted by 106 (73%) participants. Qualitative data provided further support for the challenges, with participants highlighting the lack of time to discuss complex or multiple problems, with no-one coordinating their care. This, in turn, led to polypharmacy and insufficient discussion around drug and disease interactions, complications and self-help measures. Conclusion: This study highlights the challenges for individuals with inflammatory arthritis who suffer with multiple co-morbidities. The challenges result from limited resources or support within the current health-care environments. Individuals highlighted the poor quality of life, which is multifactorial, and the need for better educational strategies and coordination of care to improve outcomes.
- 11 January 2021
- Published by Oxford University Press (OUP) in Rheumatology Advances in Practice
- Vol. 5 (1) , rkaa076
Open AccessPatient perceptions of co-morbidities in inflammatory arthritis
Objective: Longer life expectancy has resulted in people living with an increasing number of co-morbidities. The average individual with inflammatory arthritis has two co-morbidities, which contribute to higher mortality, poorer functional outcomes and increased health-care utilization and cost. A number of studies have investigated the prevalence of co-morbidities, whereas this study was designed to look at patient perspectives. Methods: The study comprised two parts: a patient questionnaire and an interview. Individuals with physician-verified inflammatory arthritis along with one or more Charlson co-morbidities were invited to participate. In-depth data were obtained by interviews with 12 willing participants. Results: One hundred and forty-six individuals were recruited; 50 (35%) had one co-morbidity, 69 (48%) had two and 25 (17%) had more than four co-morbidities. Seventy-seven individuals (53%) reported that co-morbidities affected their health as much as their arthritis, and 82 (56%) reported dependence on others for activities of daily living. Lack of education was highlighted by 106 (73%) participants. Qualitative data provided further support for the challenges, with participants highlighting the lack of time to discuss complex or multiple problems, with no-one coordinating their care. This, in turn, led to polypharmacy and insufficient discussion around drug and disease interactions, complications and self-help measures. Conclusion: This study highlights the challenges for individuals with inflammatory arthritis who suffer with multiple co-morbidities. The challenges result from limited resources or support within the current health-care environments. Individuals highlighted the poor quality of life, which is multifactorial, and the need for better educational strategies and coordination of care to improve outcomes.
- Open Access
Clinical characteristics and Outcomes of 500 patients with COVID Pneumonia – Results from a Single center (Southend University Hospital)
Objectives: To characterise the clinical features of hospitalised COVID-19 patients in a single centre during the first epidemic wave and explore potential predictive variables associated with outcomes such as mortality and the need for mechanical ventilation, using baseline clinical parameters. Methodology: We conducted a retrospective review of electronic records for demographic, clinical and laboratory data, imaging and outcomes for 500 hospitalised patients between February 20 th and May 7 th 2020 from Southend University Hospital, Essex, UK. Multivariate logistic regression models were used to identify risk factors relevant to outcome. Results: The mean age of the cohort admitted to hospital with Covid-19, was 69.4 and 290 (58%) were over 70. The majority were Caucasians, 437 (87%) with ≤2 comorbidities 280(56%). Most common were hypertension 186(37%), Cardiovascular disease 178(36%) and Diabetes 128 (26%), represented in a larger proportion on the mortality group. Mean CFS was 4 with Non - Survivors had significantly higher CFS 5 vs 3 in survivors, p<0.001. In addition, Mean CRP was significantly higher 150 vs 90, p<0.001 in Non-Survivors. We observed the baseline predictors for mortality were age, CFS and CRP. Conclusions: In this single centre study, older and frailer patients with more comorbidities and a higher baseline CRP and creatinine were risk factors for worse outcomes. Integrated frailty and age-based risk stratification are essential, in addition to monitoring SFR (Sp02/Fi02) and inflammatory markers throughout the disease course to allow for early intervention to improve patient outcomes.
Open AccessClinical characteristics and Outcomes of 500 patients with COVID Pneumonia – Results from a Single center (Southend University Hospital)
Objectives: To characterise the clinical features of hospitalised COVID-19 patients in a single centre during the first epidemic wave and explore potential predictive variables associated with outcomes such as mortality and the need for mechanical ventilation, using baseline clinical parameters. Methodology: We conducted a retrospective review of electronic records for demographic, clinical and laboratory data, imaging and outcomes for 500 hospitalised patients between February 20 th and May 7 th 2020 from Southend University Hospital, Essex, UK. Multivariate logistic regression models were used to identify risk factors relevant to outcome. Results: The mean age of the cohort admitted to hospital with Covid-19, was 69.4 and 290 (58%) were over 70. The majority were Caucasians, 437 (87%) with ≤2 comorbidities 280(56%). Most common were hypertension 186(37%), Cardiovascular disease 178(36%) and Diabetes 128 (26%), represented in a larger proportion on the mortality group. Mean CFS was 4 with Non - Survivors had significantly higher CFS 5 vs 3 in survivors, p<0.001. In addition, Mean CRP was significantly higher 150 vs 90, p<0.001 in Non-Survivors. We observed the baseline predictors for mortality were age, CFS and CRP. Conclusions: In this single centre study, older and frailer patients with more comorbidities and a higher baseline CRP and creatinine were risk factors for worse outcomes. Integrated frailty and age-based risk stratification are essential, in addition to monitoring SFR (Sp02/Fi02) and inflammatory markers throughout the disease course to allow for early intervention to improve patient outcomes.
- 1 April 2018
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 58 (4) , 559-560
Why subcutaneous methotrexate should be a prerequisite to biologic use in patients with rheumatoid arthritis
- 1 April 2018
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 58 (4) , 559-560
Why subcutaneous methotrexate should be a prerequisite to biologic use in patients with rheumatoid arthritis